Tianeptine sodium

Quick links

Choose a section

Quick links to important sections

Advertisements

Tianeptine sodium

Selected form

Advertisements
Advertisements

Method of action: Psychoanaleptics

Treatment option:

Advertisements

Overview of Tianeptine sodium

Property Description
Active Ingredient Tianeptine (INN)
Form Solid oral dosage forms (tablets, capsules)
Pharmacological Class Atypical Antidepressant (Structurally related to tricyclic compounds)
General Purpose To stabilize mood and reduce anxiety symptoms
Origin Synthetic compound

What is Tianeptine Sodium and Its Core Identity?

Tianeptine sodium is a synthetic compound defined as the specific sodium salt form of the active pharmaceutical ingredient, Tianeptine. This substance is a single-ingredient product administered via the oral route, primarily formulated as various tablets or capsules. The utilization of the sodium salt is a pharmaceutical technique designed to optimize the drug’s physical properties, notably enhancing its stability and absorption within the body. It has been clinically recognized in various global markets, particularly in Europe and Asia, for its distinct therapeutic profile compared to common Western antidepressants.

Tianeptine's Classification as an Atypical Antidepressant

Tianeptine is pharmacologically categorized as an atypical antidepressant. This classification is applied because, although its chemical structure is related to tricyclic compounds (TCA), its functional mechanism is distinct from both classic TCAs and selective serotonin reuptake inhibitors (SSRIs). It is notable for its action as a Selective Serotonin Reuptake Enhancer (SSRE), which reverses the uptake-blocking mechanism of most other widely used antidepressants. This unique action and overall profile are characterized by its role in modulating serotonin and the HPA axis, often making it a therapeutic option for patients experiencing depressive symptoms alongside chronic stress.

What is the General Purpose of Tianeptine?

The general purpose of the medication is to help stabilize mood and support the central nervous system's resilience to stress. Its activity includes the modulation of the HPA stress axis and promotion of neuroplasticity (the brain's structural and functional adaptability), alongside its action as an SSRE. These effects collectively work to restore a balanced neurochemical state, helping to alleviate feelings of persistent sadness or low spirits and generally reduce symptoms of anxiety associated with mood disturbances. For instance, it is typically used for patients needing assistance managing periods of emotional duress or generalized depressive symptoms.

Regulatory References

  1. WHO-ATC code N06AX14, NIH
Advertisements

What side effects are possible with Tianeptine sodium?

Possible Side Effects and Safety Information

The safety profile of Tianeptine sodium is officially documented, classifying potential adverse reactions by frequency and affected body system. All information reflects documented findings from government regulatory sources.

Frequency-Classified Adverse Reactions

The most frequently reported side effects are categorized as Common. Less common and more severe events are classified as Uncommon or Rare based on clinical data.

Classification Examples of Documented Effects
Common Headache, dizziness, dry mouth, constipation, nausea, abdominal pain, asthenia (weakness), palpitations, tremor, insomnia, agitation.
Uncommon Pruritus (itching), maculopapular rash, blurred vision.
Rare Hepatitis, hypomania, changes in ECG (electrocardiogram).
Not Known Extrapyramidal disorder, dyskinesia, confusion, seizures.

Serious Safety Considerations and Restrictions

Official labeling addresses clinically significant risks and limitations of use:

  • Risk of Dependence and Abuse: Tianeptine is associated with a high potential for dependence and abuse, particularly at high doses, with documented reports of severe withdrawal syndrome and strong cravings upon cessation.
  • Suicidality: The risk of suicide and suicidal thoughts persists until significant remission is achieved, requiring continued monitoring, especially during the initial stages of treatment.
  • Contraindications: The medication is contraindicated in cases of known hypersensitivity or for simultaneous use with non-selective Monoamine Oxidase Inhibitors (MAOIs). A mandatory two-week wash-out period is required when switching from an MAOI.
  • Pediatric Use: Tianeptine sodium is contraindicated in children and adolescents under 15 years old. Overdose toxicity, including respiratory depression and coma, is also documented.
Advertisements

Overdose and Emergency Response

Overdosing on Tianeptine sodium is a serious and potentially fatal medical emergency, particularly when high doses are ingested or when combined with other substances like alcohol, benzodiazepines, or other depressants. Because tianeptine acts on opioid receptors, a severe overdose can lead to symptoms that mimic opioid toxicity, including life-threatening respiratory depression.

Symptoms of Severe Overdose

Symptoms can vary widely but may include a range of serious cardiovascular and neurological effects:

  • Respiratory Issues: Severely slowed or stopped breathing (respiratory depression).
  • Neurological Impairment: Extreme drowsiness, confusion, agitation, hallucinations, seizures, and coma.
  • Cardiovascular Effects: Rapid heartbeat (tachycardia), dangerously high blood pressure, and potential for cardiac arrest.
  • Gastrointestinal Distress: Severe nausea and vomiting.

When to Seek Immediate Help

Tianeptine overdose is a critical situation requiring emergency care. If any of the above severe symptoms are observed after tianeptine ingestion, or if a person is unresponsive, has difficulty breathing, or has a seizure, call for emergency medical services immediately. In some cases, the opioid-like effects of a tianeptine overdose may be partially or fully reversed with the administration of naloxone by trained medical personnel. Always provide emergency responders with all available information regarding the substance and quantity consumed.

Advertisements

Therapeutic Uses of Tianeptine sodium

Tianeptine sodium is commonly used in contexts marked by increased discomfort or tension, relevant across domains where additional symptomatic support is needed, such as in the management of depression and associated anxiety.


Stabilization of Mood and Symptom Support

The medication is relevant in conditions characterized by periods of heightened symptoms, including major depressive disorder and persistent depressive states. It is applied in addressing core symptoms that may become intense or disruptive, such as persistent sadness, low spirits, and loss of pleasure. Supportive relief generally helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods by also helping address associated anxiety and inner tension.


Use in Specific Contexts

The medication is also considered relevant in certain complex clinical scenarios, such as managing depressive symptoms in patients with Parkinson's disease or Irritable Bowel Syndrome (IBS). It assists with maintaining functional stability and addressing symptoms that interfere with daily comfort, such as difficulties with concentration.


Quick Fact: Use in Associated Anxiety The medication is commonly used when supportive symptom management is appropriate to help address psychological tension and agitation that often accompanies low mood.

Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Tianeptine Sodium

Official regulatory documentation defines specific population groups who can and cannot use Tianeptine sodium. Use is contraindicated for patients with a known hypersensitivity to the drug or its excipients, and for children and adolescents under 15 years old. Absolute prohibition also exists for patients simultaneously taking Monoamine Oxidase Inhibitors (MAOIs).


Restricted and Conditional Use

Eligibility for certain groups is conditional on adjustment or close monitoring, as defined by prescribing labels:

  • Older Adults (> 70 years): Use is restricted and requires a mandatory dose reduction.
  • Renal Impairment: Eligibility is conditional on the use of a reduced daily dose.
  • Substance Use History: Patients with a history of dependence require close surveillance to prevent dose increases.
  • Pregnancy and Lactation: Use is generally not recommended or avoided during these periods.

Age-Specific Eligibility Status

Age Group Eligibility Status
Under 15 years Contraindicated
Adults (18–70 years) Standard Eligible Population
Over 70 years Restricted Use (Mandatory Dose Reduction)
Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Tianeptine sodium is fundamentally defined by its absolute prohibition of use with Monoamine Oxidase Inhibitors (MAOIs). This restriction is a central regulatory requirement based on the potential for a severe pharmacodynamic interaction.

Interaction Type Interacting Medicines/Classes Regulatory Constraint
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Strictly prohibited.

The official labeling mandates strict procedural constraints for switching between Tianeptine sodium and MAOIs. These rules define necessary washout periods to ensure safety:

  • A minimum period of 14 days must elapse after discontinuing an irreversible MAOI before initiating treatment with Tianeptine sodium.
  • A minimum period of 24 hours must elapse after discontinuing a reversible MAOI before initiating treatment with Tianeptine sodium.

These same respective washout periods must also be strictly observed when a patient is transitioning from Tianeptine sodium to any MAOI. No other specific medicines or classes are explicitly singled out in the primary interaction restriction sections of authoritative regulatory documents, making the interaction with MAOIs the dominant constraint on its co-administration profile.

Advertisements

Mechanism of Action

Tianeptine sodium exerts its pharmacological effects through several distinct mechanisms across central nervous system pathways. Tianeptine is characterized by its ability to enhance the reuptake of serotonin in the brain. This action targets the serotonin transporter, resulting in the modulation of synaptic transmission of this key monoamine. The compound also acts as a selective mu-opioid receptor (MOR) agonist. This interaction influences cellular signaling within brain regions associated with the stress response axis. Tianeptine further modulates the glutamatergic system by affecting the function of AMPA and NMDA receptors. This cellular activity, primarily involving ionotropic glutamate receptors, ultimately influences neuronal plasticity. Additionally, Tianeptine regulates the Hypothalamic-Pituitary-Adrenal (HPA) axis activity. This systemic regulation, coupled with the compound's direct effects on cell growth factors, influences neurogenesis within the hippocampus.

Advertisements

Dosage and Administration Information

How to Use Tianeptine Sodium

Official Administration Guidelines

Tianeptine sodium is an atypical antidepressant utilized according to specific, standardized protocols. The general principles of administration define the route, frequency, and dose adjustments required for proper use.


Dosing and Route

The approved route of administration for Tianeptine sodium is oral, typically supplied as a 12.5 mg tablet. The standard regimen for adult patients is 12.5 mg taken three times a day (T.I.D.), which constitutes a total daily dose of 37.5 mg.

Each tablet is generally instructed to be swallowed whole without crushing or chewing and is often recommended to be taken at the beginning of the main meals (morning, midday, and evening).


Population-Specific Use and Discontinuation

Specific dosage limitations are mandated for certain patient groups. For adults over 70 years of age and patients with established renal impairment, the daily dosage must be restricted to a maximum of 25 mg (two 12.5 mg tablets per day). The medicine is not to be used in children and adolescents under 15 years old.

When discontinuing the medicine, treatment must not be interrupted abruptly. Dosage is typically gradually reduced over a period of approximately 7 to 14 days to ensure the proper cessation of use. Wash-out periods are also mandatory when transitioning from or to a Monoamine Oxidase Inhibitor (MAOI).

Advertisements

Recent Clinical Evidence

Tianeptine sodium: Recent Clinical Evidence


Research Evidence for Major Depressive Disorder and Associated Anxiety

The primary research for Tianeptine sodium consists of short-term Randomized Controlled Trials (RCTs) that were used in research exploring how symptoms change over time. These studies evaluated the compound against both placebo and various active comparator antidepressants already studied for use in the general adult population, including older adult cohorts. Studies monitored changes in standardized depression rating scales and co-occurring anxiety symptoms.

Findings describe patterns observed in these short-term studies, and research describes changes measured during the acute study phase. Studies involved comparisons against other standard antidepressants, which provided data showing patterns related to symptom intensity and variability in the observed populations. However, most pivotal RCTs were short-term (typically 8 to 12 weeks), meaning highly controlled data on long-term outcomes and the duration of the measured outcomes are not fully established by this type of research.


Studies in Specific Clinical Contexts and Comorbidities

Research has also explored the compound’s application in specific clinical contexts, focusing on conditions like Parkinson's Disease, Irritable Bowel Syndrome (IBS), or Alcohol Addiction. The evidence for these subgroups is often derived from smaller-scale studies, including open-label trials and retrospective observational reviews of data from patient cohorts. Outcomes examined include changes in depressive symptoms and patient-reported outcomes describing perceived discomfort.


What is Still Uncertain About the Research Base

Despite the existing body of research, data are still emerging in several areas. The evidence for specific comorbid subgroups remains limited compared to the core MDD trials, with study designs frequently relying on open-label methodologies and modest sample sizes. Limited information is available for long-term outcomes, as many pivotal studies utilized short follow-up durations. Furthermore, comparative evidence is lacking against newer classes of widely used antidepressants, and data for certain groups remain insufficient.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tianeptine sodium (FAQ)

Q: How quickly does Tianeptine sodium start working for mood-related conditions?

Studies and official information indicate that the effectiveness of Tianeptine sodium for mood disorders is assessed over time. Clinical trials that evaluate how well the drug works typically monitor changes in symptoms using standardized rating scales over periods of 8 to 12 weeks. Observing the full therapeutic response may take several weeks.

Q: What is the general duration of action for Tianeptine sodium?

According to official product information, the drug has a short duration of action in the body. The elimination half-life, which is the time it takes for half the drug to leave the system, is approximately 2.5 hours in adults with normal kidney function. Due to this short half-life, the drug is typically administered on a multiple-times-daily regimen to maintain its therapeutic effects.

Q: What kind of withdrawal symptoms are associated with stopping Tianeptine sodium?

Regulatory documents state that when Tianeptine sodium is stopped, there is a potential for documented withdrawal symptoms. These symptoms can include signs similar to those of opioid withdrawal, such as agitation, anxiety, muscle pain, nausea, vomiting, and depression. Consultation with a healthcare provider is essential when considering discontinuing the use of Tianeptine sodium.

Q: How long do Tianeptine sodium withdrawal symptoms typically last?

The duration and intensity of withdrawal symptoms can vary from person to person. Regulatory guidance specifies that the medicine should not be interrupted abruptly and requires the dosage to be gradually reduced over a specified period to minimize discontinuation symptoms.

Q: Are there research studies comparing the effectiveness of Tianeptine sodium to traditional antidepressants?

Studies and official information indicate that Tianeptine has been evaluated in short-term clinical trials. In these randomized controlled studies, the drug was compared against both a placebo (a sugar pill) and various active comparator antidepressants to measure its effectiveness.

Q: Can Tianeptine sodium be used for conditions other than depression, such as anxiety or IBS?

The primary approved use of Tianeptine sodium is for Major Depressive Disorder. However, clinical research has also studied its effects on co-occurring anxiety symptoms often associated with mood disturbances. Additionally, studies have explored the drug's application for symptoms related to Irritable Bowel Syndrome (IBS).

Q: Can Tianeptine sodium use lead to increased risk of agitation or anxiety in some people?

Official adverse reaction lists document agitation as a common side effect of the medicine. While the drug is primarily used to address anxiety symptoms associated with depression, close monitoring for any clinical worsening, including signs of increased agitation or anxiety, is typically recommended by healthcare professionals.

Q: Does Tianeptine sodium affect the brain's opioid receptors at the typical therapeutic dose?

Yes, official pharmacological information states that Tianeptine is an atypical mu-opioid receptor (MOR) agonist. This means that it binds to and activates opioid receptors, and this action is considered part of the drug's overall mechanism in the brain.

Q: Is it safe to combine Tianeptine sodium with alcohol?

According to the official product labeling, it is advised against the concomitant use of alcohol while undergoing treatment with Tianeptine sodium. The labeling advises against concurrent use of Tianeptine sodium with alcohol.

Q: Does Tianeptine sodium interact with common over-the-counter pain relievers like aspirin?

Regulatory documents advise that concurrent use of Tianeptine with acetylsalicylic acid (Aspirin) should be approached with caution. The combination is associated with a potential for increased risk of gastrointestinal bleeding.

Q: What are the concerns about combining Tianeptine sodium with benzodiazepines or other sedatives?

Combining Tianeptine with other substances that cause Central Nervous System (CNS) depression, such as benzodiazepines or opioids, carries a significant risk. Combining these substances may increase the risk of serious adverse outcomes, including profound sedation, respiratory depression, coma, and death.

Q: Does Tianeptine sodium have any known effects on motor skills or cognition?

Regulatory documents include a warning that driving or operating complex machinery should be avoided while taking this medication. This warning is in place because the medicine may cause side effects, such as dizziness, which could impair a person's ability to perform skilled and attentive tasks.

Q: Is it possible to overdose on Tianeptine sodium, and what are the symptoms?

Yes, regulatory documentation addresses the risk of overdose. Overdose, especially when the drug is combined with alcohol or other CNS depressants, has been documented. Symptoms of a serious overdose may include respiratory depression (severely slowed breathing), confusion, coma, and seizure.

Q: Is there a risk of developing a physical dependence on Tianeptine sodium over time?

Official warnings state there is a documented risk of developing dependence and abuse associated with Tianeptine. This risk is particularly associated with non-prescribed use or taking doses higher than recommended.

Q: Are there any specific organs, like the liver or kidneys, that Tianeptine can affect?

Official information indicates that this medicine can affect certain organs. Use is restricted and requires a dose reduction in patients with renal impairment (kidney disease). Additionally, Hepatitis (inflammation of the liver) is listed as a rare potential adverse reaction in the safety data.

Q: Can Tianeptine sodium affect heart rate or blood pressure?

Official adverse reaction reports state that palpitations (feeling of a fast or irregular heartbeat) are a common side effect. Changes in the ECG (a test that records heart's electrical activity) are listed as rare effects, and hypertension has been associated with misuse.

Q: What are the reported effects of Tianeptine sodium on sexual function?

According to the official safety information, the Summary of Product Characteristics, which lists known adverse reactions, does not document sexual dysfunction as a common or uncommon side effect of Tianeptine sodium.

Advertisements

How should Tianeptine sodium be stored and disposed of?

How to Store and Dispose of Tianeptine sodium

Official regulatory documents define the storage and disposal requirements for Tianeptine sodium to ensure its stability and safe removal.

Storage and Handling Requirements

Requirement Official Statement
Temperature Store at a temperature below 30°C.
Packaging Keep the container tightly closed in the original packaging.
Stability Documented shelf-life of 36 months when stored under specified conditions.
Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Disposal must strictly follow local, state, and federal regulations. The preferred method is to use official drug take-back programs or mail-back services where available. It is strictly prohibited to allow the product to enter sewers, surface water, or ground water, emphasizing the requirement to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tianeptine sodium found in:

A-Z Index: